Neuroprotective Agents: Therapeutic Applications and Global Markets
Summary
According to the 2007 Global Burden of Disease report from the World Health Organization (WHO), more than 1 billion people worldwide suffered from neurological disorders, including stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease (PD), brain injuries, and glaucoma and other eye disorders. Nearly 7 million people died from these diseases. According to the report, one in six people is stricken by a neurological disorder every year, many of them becoming seriously disabled.
In 2015, neurological disorders ranked as the leading cause of lifelong disabilities among the main disease groups and were the second most common cause of death. Stroke is the leading neurological disorder and it affects more than 15 million people every year worldwide, killing 5 million people and leaving an equal number of people with debilitating disabilities.
In 2015, AD affected more than 46 million people, and it was the second leading cause of death, after stroke. Neurodegenerative disorders such as AD, PD, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) ranked in the 10 most fatal incurable diseases.
As life spans increase, most of the neurological disorders are becoming more prevalent. Common diseases of advanced age such as glaucoma, AD-associated dementia, age-related macular degeneration (AMD), diabetic retinopathy and PD affect nearly one-fourth of adults over 60.
In the U.S., 1.5 million people suffer from a traumatic central nervous system (CNS) injury each year. This number consists primarily of young adults and the elderly, due to reasons such as accidents, falls, sports- and work-related injuries, combat and self-harm. One-third of injury-related deaths in the U.S. are caused by traumatic brain injuries, which also lead to serious physical disabilities, cognitive disorders and neurodegenerative diseases.
Treating neurological disorders has proved to be greatly challenging. In addition to mostly insufficient clinical research in many neurological disorders, therapeutic limitations are due to a natural protective seal around the brain called the blood-brain barrier, which makes it extremely difficult to effectively diffuse a drug compound into the brain.
Neuroprotection is an approach to the treatment of neurological disorders through the use of therapies that are developed by learning from the brain’s own tools to protect nerve cells from damage, degeneration and death. The human brain, by large and small biological molecules and certain types of cells, can promote growth, survival and differentiation to adapt to sudden changes, trauma and disease. Neuroprotective agents in global markets and clinical pipelines include small molecule drugs, therapeutic monoclonal antibodies, gene therapies, cell therapies and other agents.
The global market for neuroprotective agents was valued at $REDACTED billion in 2016 and $REDACTED billion. in 2017
According to the 2007 Global Burden of Disease report from the World Health Organization (WHO), more than 1 billion people worldwide suffered from neurological disorders, including stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease (PD), brain injuries, and glaucoma and other eye disorders. Nearly 7 million people died from these diseases. According to the report, one in six people is stricken by a neurological disorder every year, many of them becoming seriously disabled.
In 2015, neurological disorders ranked as the leading cause of lifelong disabilities among the main disease groups and were the second most common cause of death. Stroke is the leading neurological disorder and it affects more than 15 million people every year worldwide, killing 5 million people and leaving an equal number of people with debilitating disabilities.
In 2015, AD affected more than 46 million people, and it was the second leading cause of death, after stroke. Neurodegenerative disorders such as AD, PD, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) ranked in the 10 most fatal incurable diseases.
As life spans increase, most of the neurological disorders are becoming more prevalent. Common diseases of advanced age such as glaucoma, AD-associated dementia, age-related macular degeneration (AMD), diabetic retinopathy and PD affect nearly one-fourth of adults over 60.
In the U.S., 1.5 million people suffer from a traumatic central nervous system (CNS) injury each year. This number consists primarily of young adults and the elderly, due to reasons such as accidents, falls, sports- and work-related injuries, combat and self-harm. One-third of injury-related deaths in the U.S. are caused by traumatic brain injuries, which also lead to serious physical disabilities, cognitive disorders and neurodegenerative diseases.
Treating neurological disorders has proved to be greatly challenging. In addition to mostly insufficient clinical research in many neurological disorders, therapeutic limitations are due to a natural protective seal around the brain called the blood-brain barrier, which makes it extremely difficult to effectively diffuse a drug compound into the brain.
Neuroprotection is an approach to the treatment of neurological disorders through the use of therapies that are developed by learning from the brain’s own tools to protect nerve cells from damage, degeneration and death. The human brain, by large and small biological molecules and certain types of cells, can promote growth, survival and differentiation to adapt to sudden changes, trauma and disease. Neuroprotective agents in global markets and clinical pipelines include small molecule drugs, therapeutic monoclonal antibodies, gene therapies, cell therapies and other agents.
The global market for neuroprotective agents was valued at $REDACTED billion in 2016 and $REDACTED billion. in 2017
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Neuroprotection
Why Are Neuroprotective Therapies Needed?
Neuroprotective Strategies
Cerebrovascular Disease
Stroke
Neuroprotection in Stroke
Neurodegenerative Disorders
Parkinson's Disease
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Alzheimer's Disease
Huntington's Disease
Spinal Muscular Atrophy
Epilepsy
Neuroprotection in Neurodegenerative Disorders
Ophthalmic Diseases
Glaucoma
Nonarteritic Anterior Ischemic Optic Neuropathy
Age-related Macular Degeneration
Diabetic Retinopathy
Neuroprotection in Ophthalmic Diseases
Traumatic CNS Injuries
Traumatic Brain Injury
Traumatic Spinal Cord Injuries
Neuroprotection in Traumatic CNS Injuries
CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Therapeutic Agents
Antisense Agents
Anti-amyloid Agents
Immune Response Modifiers
Antioxidants
Anti-angiogenic Agents
Anti-Parkinson's Agents
Anticonvulsants
Ocular Hypotensives
Thrombolytics
Blood Thinning Agents
Anti-dementia Agents
Other Neuroprotective Agents
Regenerative Medicine Products
Brainstorm Cell Therapeutics' Nurown as First ALS Cell Therapy in the U.S.
Neuronata-R to Expand to International ALS Markets
Multistem Fast-tracked for Ischemic Stroke
CEVA101 Advances in Traumatic Brain Injury Trials
Asterias Biotherapeutics Snatches RMAT for Spinal Cord Injuries
CTX0E03 Advances in PISCES II Trials for Stroke Disability
CHAPTER 5 MARKET BREAKDOWN BY THERAPEUTIC INDICATION
Neuroprotective Agents for Cerebrovascular Disease
Neuroprotective Agents for Neurodegenerative Disorders
Neuroprotective Agents for Ophthalmic Diseases
Neuroprotective Agents for Traumatic Central Nervous System Injuries
CHAPTER 6 MARKET BREAKDOWN BY REGION
CHAPTER 7 COMPANY PROFILES
AB SCIENCE S.A.
ACUCELA INC.
AERIE PHARMACEUTICALS INC.
ALLERGAN
ASTRAZENECA PLC
ATHERSYS INC.
AVEXIS INC.
BAYER HEALTHCARE
BIOGEN INC.
BRISTOL-MYERS SQUIBB CO.
BOEHRINGER INGELHEIM
BRAINSTORM CELL THERAPEUTICS INC.
CELGENE CORP.
CORESTEM INC.
COVIS PHARMA
DAIICHI SANKYO INC.
EISAI INC.
FORTRESS BIOTECH INC.
GENERVON BIOPHARMACEUTICALS LLC
GLAXOSMITHKLINE PLC
GW PHARMACEUTICALS PLC
H. LUNDBECK A/S
JANSSEN PHARMACEUTICALS INC.
MEDDAY PHARMACEUTICALS SAS
MERCK SERONO S.A.
MITSUBISHI PHARMA CORP.
NEWRON PHARMACEUTICALS SPA
NOVARTIS AG
PFIZER INC.
QUARK PHARMACEUTICALS INC.
REGENERON PHARMACEUTICALS INC.
RENEURON GROUP PLC
ROCHE HOLDING AG
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB PHARMA S.A.
VERTEX PHARMACEUTICALS INC.
VTV THERAPEUTICS INC.
ZOGENIX INC.
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Neuroprotection
Why Are Neuroprotective Therapies Needed?
Neuroprotective Strategies
Cerebrovascular Disease
Stroke
Neuroprotection in Stroke
Neurodegenerative Disorders
Parkinson's Disease
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Alzheimer's Disease
Huntington's Disease
Spinal Muscular Atrophy
Epilepsy
Neuroprotection in Neurodegenerative Disorders
Ophthalmic Diseases
Glaucoma
Nonarteritic Anterior Ischemic Optic Neuropathy
Age-related Macular Degeneration
Diabetic Retinopathy
Neuroprotection in Ophthalmic Diseases
Traumatic CNS Injuries
Traumatic Brain Injury
Traumatic Spinal Cord Injuries
Neuroprotection in Traumatic CNS Injuries
CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Therapeutic Agents
Antisense Agents
Anti-amyloid Agents
Immune Response Modifiers
Antioxidants
Anti-angiogenic Agents
Anti-Parkinson's Agents
Anticonvulsants
Ocular Hypotensives
Thrombolytics
Blood Thinning Agents
Anti-dementia Agents
Other Neuroprotective Agents
Regenerative Medicine Products
Brainstorm Cell Therapeutics' Nurown as First ALS Cell Therapy in the U.S.
Neuronata-R to Expand to International ALS Markets
Multistem Fast-tracked for Ischemic Stroke
CEVA101 Advances in Traumatic Brain Injury Trials
Asterias Biotherapeutics Snatches RMAT for Spinal Cord Injuries
CTX0E03 Advances in PISCES II Trials for Stroke Disability
CHAPTER 5 MARKET BREAKDOWN BY THERAPEUTIC INDICATION
Neuroprotective Agents for Cerebrovascular Disease
Neuroprotective Agents for Neurodegenerative Disorders
Neuroprotective Agents for Ophthalmic Diseases
Neuroprotective Agents for Traumatic Central Nervous System Injuries
CHAPTER 6 MARKET BREAKDOWN BY REGION
CHAPTER 7 COMPANY PROFILES
AB SCIENCE S.A.
ACUCELA INC.
AERIE PHARMACEUTICALS INC.
ALLERGAN
ASTRAZENECA PLC
ATHERSYS INC.
AVEXIS INC.
BAYER HEALTHCARE
BIOGEN INC.
BRISTOL-MYERS SQUIBB CO.
BOEHRINGER INGELHEIM
BRAINSTORM CELL THERAPEUTICS INC.
CELGENE CORP.
CORESTEM INC.
COVIS PHARMA
DAIICHI SANKYO INC.
EISAI INC.
FORTRESS BIOTECH INC.
GENERVON BIOPHARMACEUTICALS LLC
GLAXOSMITHKLINE PLC
GW PHARMACEUTICALS PLC
H. LUNDBECK A/S
JANSSEN PHARMACEUTICALS INC.
MEDDAY PHARMACEUTICALS SAS
MERCK SERONO S.A.
MITSUBISHI PHARMA CORP.
NEWRON PHARMACEUTICALS SPA
NOVARTIS AG
PFIZER INC.
QUARK PHARMACEUTICALS INC.
REGENERON PHARMACEUTICALS INC.
RENEURON GROUP PLC
ROCHE HOLDING AG
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB PHARMA S.A.
VERTEX PHARMACEUTICALS INC.
VTV THERAPEUTICS INC.
ZOGENIX INC.
LIST OF TABLES
Summary Table: Global Market for Neuroprotective Agents, by Region, Through 2022
Table 1: Global Market for Neuroprotective Agents, by Technology Type, Through 2022
Table 2: Global Market for Neuroprotective Agents, by Application, Through 2022
Table 3: Global Market for Therapeutic Agents, by Drug Class, Through 2022
Table 4: Global Market for Antisense Agents, Through 2022
Table 5: Global Market for Anti-Amyloid Agents, Through 2022
Table 6: Neuroprotective Interferons Available in Global Markets, by Brand
Table 7: Neuroprotective Monoclonal Antibodies Available in Global Markets, by Brand
Table 8: Key Immune Response Modifiers in Clinical Development
Table 9: Global Market for Immune Response Modifiers, Through 2022
Table 10: Key Antioxidants in Clinical Development
Table 11: Global Market for Antioxidants, Through 2022
Table 12: Key Anti-angiogenic Agents in Clinical Development
Table 13: Global Market for Anti-Angiogenic Agents, Through 2022
Table 14: Global Market for Anti-Parkinson’s Agents, Through 2022
Table 15: Key Anticonvulsants in Clinical Development
Table 16: Global Market for Anticonvulsants, Through 2022
Table 17: Global Market for Ocular Hypotensives, Through 2022
Table 18: Global Market for Thrombolytics, Through 2022
Table 19: Global Market for Blood Thinning Agents, Through 2022
Table 20: Global Market for Anti-Dementia Agents, Through 2022
Table 21: Key Neuroprotective Drug Candidates with Novel MoA in Clinical Development
Table 22: Global Market for Other Neuroprotective Agents, Through 2022
Table 23: Global Market for Regenerative Medicine Products, Through 2022
Table 24: Global Market Share for Key Players in Neuroprotection, 2017
Table 25: Global Market for Neuroprotective Agents, by Therapeutic Indication, Through 2022
Table 26: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, Through 2022
Table 27: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, Through 2022
Table 28: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, Through 2022
Table 29: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, Through 2022
Table 30: Global Market for Neuroprotective Agents, by Region, Through 2022
Table 31: North American Market for Neuroprotective Agents, by Indication, Through 2022
Table 32: European Market for Neuroprotective Agents, by Indication, Through 2022
Table 33: Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2022
Table 34: ROW Market for Neuroprotective Agents, by Indication, Through 2022
Table 35: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, Through 2022
Table 36: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, Through 2022
Table 37: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, Through 2022
Table 38: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, Through 2022
Summary Table: Global Market for Neuroprotective Agents, by Region, Through 2022
Table 1: Global Market for Neuroprotective Agents, by Technology Type, Through 2022
Table 2: Global Market for Neuroprotective Agents, by Application, Through 2022
Table 3: Global Market for Therapeutic Agents, by Drug Class, Through 2022
Table 4: Global Market for Antisense Agents, Through 2022
Table 5: Global Market for Anti-Amyloid Agents, Through 2022
Table 6: Neuroprotective Interferons Available in Global Markets, by Brand
Table 7: Neuroprotective Monoclonal Antibodies Available in Global Markets, by Brand
Table 8: Key Immune Response Modifiers in Clinical Development
Table 9: Global Market for Immune Response Modifiers, Through 2022
Table 10: Key Antioxidants in Clinical Development
Table 11: Global Market for Antioxidants, Through 2022
Table 12: Key Anti-angiogenic Agents in Clinical Development
Table 13: Global Market for Anti-Angiogenic Agents, Through 2022
Table 14: Global Market for Anti-Parkinson’s Agents, Through 2022
Table 15: Key Anticonvulsants in Clinical Development
Table 16: Global Market for Anticonvulsants, Through 2022
Table 17: Global Market for Ocular Hypotensives, Through 2022
Table 18: Global Market for Thrombolytics, Through 2022
Table 19: Global Market for Blood Thinning Agents, Through 2022
Table 20: Global Market for Anti-Dementia Agents, Through 2022
Table 21: Key Neuroprotective Drug Candidates with Novel MoA in Clinical Development
Table 22: Global Market for Other Neuroprotective Agents, Through 2022
Table 23: Global Market for Regenerative Medicine Products, Through 2022
Table 24: Global Market Share for Key Players in Neuroprotection, 2017
Table 25: Global Market for Neuroprotective Agents, by Therapeutic Indication, Through 2022
Table 26: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, Through 2022
Table 27: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, Through 2022
Table 28: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, Through 2022
Table 29: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, Through 2022
Table 30: Global Market for Neuroprotective Agents, by Region, Through 2022
Table 31: North American Market for Neuroprotective Agents, by Indication, Through 2022
Table 32: European Market for Neuroprotective Agents, by Indication, Through 2022
Table 33: Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2022
Table 34: ROW Market for Neuroprotective Agents, by Indication, Through 2022
Table 35: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, Through 2022
Table 36: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, Through 2022
Table 37: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, Through 2022
Table 38: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, Through 2022
LIST OF FIGURES
Summary Figure: Global Market for Neuroprotective Agents, by Region, 2016-2022
Figure 1: Global Market for Neuroprotective Agents, by Technology Type, 2016-2022
Figure 2: Global Market for Neuroprotective Agents, by Application, 2016-2022
Figure 3: Global Market for Therapeutic Agents, by Drug Class, 2016-2022
Figure 4: Global Market for Antisense Agents, 2016-2022
Figure 5: Global Market for Anti-Amyloid Agents, 2016-2022
Figure 6: Global Market for Immune Response Modifiers, 2016-2022
Figure 7: Global Market for Antioxidants, 2016-2022
Figure 8: Global Market for Anti-Angiogenic Agents, 2016-2022
Figure 9: Global Market for Anti-Parkinson’s Agents, 2016-2022
Figure 10: Global Market for Anticonvulsants, 2016-2022
Figure 11: Global Market for Ocular Hypotensives, 2016-2022
Figure 12: Global Market for Thrombolytics, 2016-2022
Figure 13: Global Market for Blood Thinning Agents, 2016-2022
Figure 14: Global Market for Anti-Dementia Agents, 2016-2022
Figure 15: Global Market for Other Neuroprotective Agents, 2016-2022
Figure 16: Global Market for Regenerative Medicine Products, 2016-2022
Figure 17: Global Market Share for Key Players in Neuroprotection, 2017
Figure 18: Global Market for Neuroprotective Agents, by Therapeutic Indication, 2016-2022
Figure 19: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, 2016-2022
Figure 20: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, 2017-2022
Figure 21: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, 2016-2022
Figure 22: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, 2016-2022
Figure 23: Global Market for Neuroprotective Agents, by Region, 2016-2022
Figure 24: North American Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 25: European Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 26: Asia-Pacific Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 27: ROW Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 28: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, 2016-2022
Figure 29: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, 2016-2022
Figure 30: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, 2016-2022
Figure 31: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, 2016-2022
Summary Figure: Global Market for Neuroprotective Agents, by Region, 2016-2022
Figure 1: Global Market for Neuroprotective Agents, by Technology Type, 2016-2022
Figure 2: Global Market for Neuroprotective Agents, by Application, 2016-2022
Figure 3: Global Market for Therapeutic Agents, by Drug Class, 2016-2022
Figure 4: Global Market for Antisense Agents, 2016-2022
Figure 5: Global Market for Anti-Amyloid Agents, 2016-2022
Figure 6: Global Market for Immune Response Modifiers, 2016-2022
Figure 7: Global Market for Antioxidants, 2016-2022
Figure 8: Global Market for Anti-Angiogenic Agents, 2016-2022
Figure 9: Global Market for Anti-Parkinson’s Agents, 2016-2022
Figure 10: Global Market for Anticonvulsants, 2016-2022
Figure 11: Global Market for Ocular Hypotensives, 2016-2022
Figure 12: Global Market for Thrombolytics, 2016-2022
Figure 13: Global Market for Blood Thinning Agents, 2016-2022
Figure 14: Global Market for Anti-Dementia Agents, 2016-2022
Figure 15: Global Market for Other Neuroprotective Agents, 2016-2022
Figure 16: Global Market for Regenerative Medicine Products, 2016-2022
Figure 17: Global Market Share for Key Players in Neuroprotection, 2017
Figure 18: Global Market for Neuroprotective Agents, by Therapeutic Indication, 2016-2022
Figure 19: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, 2016-2022
Figure 20: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, 2017-2022
Figure 21: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, 2016-2022
Figure 22: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, 2016-2022
Figure 23: Global Market for Neuroprotective Agents, by Region, 2016-2022
Figure 24: North American Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 25: European Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 26: Asia-Pacific Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 27: ROW Market for Neuroprotective Agents, by Indication, 2016-2022
Figure 28: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, 2016-2022
Figure 29: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, 2016-2022
Figure 30: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, 2016-2022
Figure 31: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, 2016-2022
